GuidelineGynecologic oncology2020
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
Guideline in Gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Factors influencing the performance of clinical research networks to improve the success of cancer clinical trials: A scoping review and organizational analysis.Journal of clinical and translational science · 2026Review
- Telehealth in Gynecologic Oncology Clinical Trials: Qualitative Study of Patient, Researcher, and Clinician Perspectives.O&G open · 2024Article
- Screening log: Challenges in community patient recruitment for gynecologic oncology clinical trials.Contemporary clinical trials communications · 2024Article
- Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic.Archives of gynecology and obstetrics · 2024Article
- TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.Cancer medicine · 2024Article
- Telehealth utilization in gynecologic oncology clinical trials.Gynecologic oncology · 2023Article
- Impact of the COVID-19 pandemic on training conditions and education in oncologic disciplines: a survey-based analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
- Maintenance therapy for long-term control of high-grade endometrial stromal sarcoma.BMJ case reports · 2022Article
- Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care.Gynecologic oncology reports · 2022Article
- Nationwide Survey of German Outpatient Gynecologic Oncology Practices during the Coronavirus Disease 2019 Pandemic: Reactions to the First Wave and Future Perspectives.Breast care (Basel, Switzerland) · 2021Article
- Being in touch: narrative assessment of patients receiving online integrative oncology treatments during COVID-19.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Article
- Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum.Gynecologic oncology · 2021Article
- Non-pharmaceutical interventions during the COVID-19 pandemic: A review.Physics reports · 2021Review
- COVID-19 and gynecological cancers: Asia and Oceania Federation of Obstetrics and Gynecology oncology committee opinion.The journal of obstetrics and gynaecology research · 2021Article
- Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic.Gynecologic oncology · 2021Observational
- Survey of cancer care providers' attitude toward care for older adults with cancer during the COVID-19 pandemic.Journal of geriatric oncology · 2021Article
- Effect of delay in surgical therapy for early-stage cervical cancer: An implication in the coronavirus pandemic.European journal of cancer (Oxford, England : 1990) · 2020Observational
- Cancer Management During the COVID-19 Pandemic in the United States: Results From a National Physician Cross-sectional Survey.American journal of clinical oncology · 2020Article
- Alternative management for gynecological cancer care during the COVID-2019 pandemic: A Latin American survey.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe COVID-19 pandemic has consumed considerable resources and has impacted the delivery of cancer care. Patients with cancer may have factors which place them at high risk for COVID 19 morbidity or mortality. Highly immunosuppressive chemotherapy regimens and possible exposure to COVID-19 during treatment may put patients at additional risk. The Society of Gynecologic Oncology convened an expert panel to address recommendations for best practices during this crisis to minimize risk to patients from deviations in cancer care and from COVID-19 morbidity.
methodsAn expert panel convened to develop initial consensus guidelines regarding anti-neoplastic therapy during the COVID-19 pandemic with respect to gynecologic cancer care and clinical trials.
resultsCOVID-19 poses special risks to patients who are older, have medical co-morbidities, and cancer. In addition, this pandemic will likely strain resources, making delivery of cancer care or conduct of clinical trials unpredictable. Recommendations are to limit visits and contact with health care facilities by using telemedicine when appropriate, and choosing regimens which require less frequent visits and which are less immunosuppressive. Deviations will occur in clinical trials as a result of limited resources, and it is important to understand regulatory obligations to trial sponsors as well as to the IRB to ensure that clinical trial and patient safety oversight are maintained.
conclusionsThe ongoing crisis will strain resources needed to deliver cancer care. When alterations to the delivery of care are mandated, efforts should be taken to minimize risks and maximize safety while approximating standard practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.